International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:
“A new Korean-language episode of Lung Cancer Considered explores the evolving role of immunotherapy across the lung cancer treatment continuum.
Dr. Chul Kim is joined by Dr. Hye Ryun Kim and Dr. Young Kwang Chae to discuss perioperative strategies for resectable NSCLC, treatment selection and biomarkers in advanced disease, emerging research, and what they’re looking forward to at WCLC 2026 in Seoul.
This also can be interesting: Ivonescimab Plus Chemotherapy Shows Powerful Benefit After EGFR-TKI Resistance in Advanced Lung Cancer
